Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
4.100
-0.010 (-0.24%)
At close: Mar 28, 2025, 4:00 PM
3.910
-0.190 (-4.64%)
Pre-market: Mar 31, 2025, 8:48 AM EDT

Lexeo Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
--0.651.660.52
Revenue Growth (YoY)
---60.53%219.59%-
Cost of Revenue
74.0953.1349.1645.124.32
Gross Profit
-74.09-53.13-48.51-43.46-3.8
Selling, General & Admin
31.6815.38127.170.79
Operating Expenses
31.6815.38127.170.79
Operating Income
-105.77-68.51-60.51-50.64-4.59
Interest Expense
-0.14-0.21-0.09--0.15
Interest & Investment Income
7.562.871.330.02-
Other Non Operating Income (Expenses)
-0.01-0.54-0-0
EBT Excluding Unusual Items
-98.36-66.39-59.28-50.62-4.73
Gain (Loss) on Sale of Investments
0.02----
Other Unusual Items
-----0.42
Pretax Income
-98.33-66.39-59.28-50.62-5.15
Net Income
-98.33-66.39-59.28-50.62-5.15
Net Income to Common
-98.33-66.39-59.28-50.62-5.15
Shares Outstanding (Basic)
325221
Shares Outstanding (Diluted)
325221
Shares Change (YoY)
493.67%228.42%5.00%7.72%-
EPS (Basic)
-3.09-12.40-36.36-32.60-3.57
EPS (Diluted)
-3.09-12.40-36.36-32.60-3.57
Free Cash Flow
-81.63-59.61-55.23-44.37-3.13
Free Cash Flow Per Share
-2.57-11.13-33.88-28.58-2.17
Operating Margin
---9252.14%-3055.94%-884.86%
Profit Margin
---9063.76%-3055.04%-993.83%
Free Cash Flow Margin
---8445.26%-2677.73%-604.35%
EBITDA
-105.14-67.94-60.24-50.62-
D&A For EBITDA
0.630.580.270.01-
EBIT
-105.77-68.51-60.51-50.64-4.59
Revenue as Reported
--0.651.660.52
Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q